MOKAN Wealth Management Inc. Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

MOKAN Wealth Management Inc. lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,280 shares of the biopharmaceutical company's stock after selling 2,499 shares during the period. Gilead Sciences accounts for about 1.1% of MOKAN Wealth Management Inc.'s portfolio, making the stock its 29th biggest holding. MOKAN Wealth Management Inc.'s holdings in Gilead Sciences were worth $1,824,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of GILD. Annis Gardner Whiting Capital Advisors LLC raised its holdings in Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 216 shares during the last quarter. Whipplewood Advisors LLC bought a new position in Gilead Sciences during the fourth quarter worth $35,000. Synergy Investment Management LLC acquired a new position in Gilead Sciences in the fourth quarter valued at $40,000. Lee Danner & Bass Inc. bought a new stake in Gilead Sciences during the fourth quarter valued at $41,000. Finally, Investment Research & Advisory Group Inc. grew its holdings in Gilead Sciences by 33.3% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 100 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Price Performance

Shares of GILD stock traded down $1.27 during trading hours on Wednesday, reaching $105.93. The stock had a trading volume of 6,053,341 shares, compared to its average volume of 7,645,261. The stock's fifty day simple moving average is $106.19 and its 200 day simple moving average is $103.01. The firm has a market capitalization of $131.77 billion, a PE ratio of 22.30, a PEG ratio of 0.69 and a beta of 0.29. Gilead Sciences, Inc. has a 12 month low of $66.01 and a 12 month high of $119.96. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period last year, the firm earned ($1.32) EPS. The business's quarterly revenue was down .3% compared to the same quarter last year. On average, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.98%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.

Analysts Set New Price Targets

GILD has been the topic of a number of research reports. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Oppenheimer cut their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Morgan Stanley upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Finally, Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $275,425.00. Following the transaction, the chief financial officer now owns 165,110 shares in the company, valued at $18,190,168.70. The trade was a 1.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the transaction, the chief executive officer now directly owns 620,268 shares of the company's stock, valued at $68,489,992.56. The trade was a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,500 shares of company stock valued at $5,236,245 over the last 90 days. 0.27% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.